Leo's doing the right thing by not disclosing the location. Some of us knew what happened to AVXL. Since Anavex 2-73 was open-label, the media reported a patient regained her ability to play piano. As a result, its stock went up 23% and the expectations were sky-high. When the efficacy data weren't as good as expected, its stock collapsed.

Quote:

---

They are mad that their investigators can't go and try to find out information before it's publicly disclosed, I guess.

---